NICE has turned down Tagrisso in the past in previously-untreated, EGFR-positive NSCLC but has now given its blessing to that use of the drug, as well as for second-line treatment of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback